Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Total Liabilities (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Total Liabilities for 2 consecutive years, with $119.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 123.3% to $119.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $119.4 million through Dec 2025, up 123.3% year-over-year, with the annual reading at $119.4 million for FY2025, 123.3% up from the prior year.
  • Total Liabilities hit $119.4 million in Q4 2025 for Xilio Therapeutics, down from $141.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $141.8 million in Q3 2025 to a low of $53.5 million in Q4 2024.